Clinical Observation of Bailing Capsules in Preventing Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients with PD-1 Inhibitor
Objective To investigate the clinical effect of bailing capsules on prevention of checkpoint inhibitor pneumonitis(CIP)in lung cancer patients with PD-1 inhibitor.Methods A total of 60 patients with advanced lung cancer who were admitted to the Department of Oncology of Jiujiang First People's Hospital from May 2021 to May 2022 and were treated with immune checkpoint inhibitors(ICIs)were divided into control group and experimental group according to random number table method,with 30 cases in each group.The control group was treated with PD-1 inhibitor,and the experimental group was treated with oral bailing capsules on the basis of the control group.The clinical efficacy,quality of life(KPS scores),adverse reactions,survival after 1 year and CIP occurrence were compared between the two groups.Results After 4 cycles of treatment,the disease control rate(DCR)of the experimental group was higher than that of the control group,the difference was statistically significant(P＜0.05).There was no significant difference in KPS scores between the two groups before treatment(P＞0.05).After 4 cycles of treatment,the KPS scores of both groups was higher than that before treatment,and the KPS scores of the experimental group was higher than that of the control group,with statistical significance(P＜0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group,the difference was statistically significant(P＜0.05).After 1-year follow-up,the survival rate of the experimental group was 90.00％(27/30),which was higher than that of the control group 63.33％(19/30),the difference was statistically significant(P＜0.05).The incidence of CIP in the experimental group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion The treatment of lung cancer patients with PD-1 inhibitor with bailing capsules can effectively improve the condition of patients,improve the quality of life of patients,reduce the risk of CIP,have fewer adverse reactions,are safe and reliable,and can improve the survival rate of patients,worthy of promotion and application.
Lung cancerCarrilizumabBailing capsulesCheckpoint inhibitor pneumonitisQuality of life scoresSurvival rate
万方数据
维普
